Rapamycin and cisplatin in breast cancers biology essay

rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase.

Several chemotherapy regimens have been reported in literature, including anthracyclines and/or taxanes containing combinations routinely used for other types of breast cancer and also combinations of platinum agents and etoposide, usually administered for small-cell lung cancer. Breast cancer is the second most common cancer in the world and the incidence of female breast cancer has continuously increased in 2013, 18 million incident cases of breast cancer occurred, and the disease caused 464,000 deaths [ 1 . In particular, rapamycin and its analogs have shown antitumor activity across a variety of human cancers in clinical trials although, classically, rapamycin actions are ascribed to inhibition of mtor, recent studies indicate fkbp51 is also an important molecular determinant of the drug’s anticancer activity. The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen‑activated protein kinase (mapk) inhibitor, on the sensitivity of cisplatin‑resistant ovarian cancer to cisplatin the expression and distribution of phosphorylated p38 mapk (p‑p38 mapk) was. To receive news and publication updates for the scientific world journal, enter your email address in the box below other investigators have shown that rapamycin enhances the effect of cisplatin and carboplatin in ovarian and breast cancer v l bae-jump, c zhou, j f boggess, and p a gehrig, “synergistic effect of rapamycin and.

rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase.

Rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), is an immunosuppressive agent that has anti-proliferative effects on some tumors this study aims to investigate the effects of rapa suppressing proliferation of pancreatic carcinoma pc-2 cells in vitro and its molecular mechanism involved in antitumor activities. Overexpression of her-2/neu occurs in about 25–30% of breast cancer patients and is indicative of poor prognosis while her2/neu overexpression is primarily a result of erbb2 amplification, it has recently been recognized that erbb2 levels are also regulated on the protein level. These results demonstrated that rapamycin is capable of sensitizing basal-like breast cancer cells to cisplatin, suggesting that the synergistic effects of rapamycin and cisplatin may be mediated through a common pathway.

Because rapamycin is known to enhance the cytotoxicity of chemotherapeutic drugs, the authors' goal was to examine the effects of rapamycin and cisplatin in endometrial cancer cell lines methods: by using ishikawa and ecc-1 cells, cell proliferation was assessed after exposure to rapamycin, cisplatin, or both in combination. Strikingly, rapamycin increased the ability of the alkylating agent, cisplatin, to induce apoptosis in the human promyelocytic leukemia cell line hl-60 and the human ovarian cancer cell line skov3. The platinum chemotherapeutic agent, cisplatin, is a major frontline drug to treat various human malignant tumors, including lung cancer 7,8 nonetheless, clinical usage of this drug is limited because of intrinsic and acquired resistance 9 to date, mounting evidence indicates that cisplatin resistance has a multifactorial nature, and the. Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and to treat a rare lung disease called lymphangioleiomyomatosis [4] [5] [6] it has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. Breast cancer overexpression of (pi3k)/mechanistic target of rapamycin (mtor) signaling transduction pathway is commonly deregulated in breast cancer and represents a potential target results of a multicentre, phase ii study have shown that bevacizumab preconditioning followed by etoposide and cisplatin (beep) is a highly effective.

Researchers at the massachusetts general hospital cancer center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment. Sirolimus, cisplatin, and gemcitabine hydrochloride in treating patients with bladder cancer the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines combination of everolimus also known as rad001 (oral mammalian target of rapamycin (mtor) inhibitor) and carboplatin may have activity in metastatic triple-negative breast. Together, these results suggest that tap73 is required to exert the synergistic effects of rapamycin and cisplatin in basal-like breast cancers, and the combination of mtor inhibitors and cisplatin may be a useful therapeutic strategy in the treatment of basal-like breast cancers. Abstract triolimus is a first-in-class, multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-aag in this study, we examine the antitumor mechanisms of action, efficacy, and toxicity of triolimus in vitro and in vivoin vitro cytotoxicity testing of triolimus was conducted using two aggressive adenocarcinomas including the lung cancer cell line, a549, and breast cancer cell line.

rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase.

Suppression of rapamycin-induced akt phosphorylation restored rapamycin sensitivity in smad4-null, but not smad4 wild-type pancreatic cancer cells this study shows that the synthetic lethality to rapamycin in pancreatic cancers with defective tgf-β signaling is masked by rapamycin-induced increases in akt phosphorylation. The mammalian target of rapamycin (mtor) pathway is a central pathway that regulates mrna translation, protein synthesis, glucose metabolism, lipid synthesis and autophagy, and is involved in malignant transformation. Cisplatin, a common chemotherapeutic agent, is used to treat many different tumors, including those caused by testicular, breast and brain cancers its dosage is limited due to its adverse side effects on the kidneys: 30 percent of patients treated with cisplatin experience a sudden loss of kidney function or acute kidney injury.

Metformin as a protective factor for gastric cancer patients with dm metformin can reduce the incidence and mortality for certain cancers, notably breast and colorectal carcinomas [15–18]however, little is known about the impact of metformin use on gastric cancer. Definition and characteristics of triple-negative breast cancers breast cancer is the leading cancer among women improved screening, imaging and treatment have improved survival.

Developments use of biomarkers to monitor marine pollution biology essay rapamycin and cisplatin in breast cancers biology essay the effect of human papillomavirus on head-and-neck cancers. Endogenous p73 is required for the synergism between rapamycin and cisplatin in basal-like breast cancer cells specific and effective knock-down of endogenous tap73 in mda-mb-231 and mda-mb-468. Read a phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer, international journal of radiation oncology biology physics on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Rapamycin and rapamycin analogues have demonstrated impressive growth-inhibitory effects against a broad range of human cancers, including breast cancer, in preclinical and early clinical evaluations.

rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase. rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase. rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase. rapamycin and cisplatin in breast cancers biology essay The phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (pi3k/akt/mtor) pathway is often constitutively activated in drug-resistant breast cancer, and this activation is correlated with increased cell survival and poor prognosis for breast cancer patients mtor is a serine/threonine kinase of the pi3k-related kinase.
Rapamycin and cisplatin in breast cancers biology essay
Rated 4/5 based on 38 review

2018.